Visalytics
Visalytics
approved EB-2 (NIW) RFE Issued

R&D/MFG Scientist III

Biopharmaceuticals/Pharmaceuticals · India · 2025-02-08

Processing Time
111 days
Decision Date
2025-02-08
Location
North Carolina
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to improve existing therapies by applying advanced pharmaceutical principles to commercialize biopharmaceuticals and pharmaceuticals. The work focuses on developing innovative drug solubility enhancement methods and non-invasive oral drug delivery systems to treat serious diseases like cancer, AIDS, and kidney failure.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses critical challenges in treating life-threatening conditions and aligns with U.S. public health goals.

2 Well Positioned to Advance the Endeavor Met

The petitioner has a record of 7 publications, 21 citations, and has served as a peer reviewer for 9 manuscripts.

3 Balance of Factors to Waive Job Offer Met

The petitioner's contributions to drug delivery systems make it beneficial for the U.S. to waive the labor certification requirement.

Why This Petition Was Approved

The petition was approved based on the client's M.Pharm. degree and a record of 7 peer-reviewed journal articles cited 21 times. Evidence included 9 manuscript reviews for journals and 2 independent letters of recommendation, satisfying all three Dhanasar prongs.

Request for Evidence (RFE)

Successfully Addressed

The case received an RFE which was successfully addressed by providing further documentation of the petitioner's impact and alignment with national healthcare priorities.

RFE Targets
Substantial Merit and National ImportanceWell Positioned to Advance the Endeavor

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Reference Letters Independent
Judging Experience
Original Contributions
Government Alignment

Similar Cases

Others

Pharmaceuticals · South Korea

WeGreened EB-2 (NIW) approved
54 days 2025-03-24
The petitioner proposes to continue her research in pharmaceutical science by integrating advanced technologies and computational approaches to develop novel drug candidates. Her work focuses on improving drug delivery systems to create more effective, affordable, and stable medications for chronic diseases including cancer, diabetes, hypertension, and neurodegenerative diseases.
View Case

Associate Professor

Pharmaceuticals · Saudi Arabia

WeGreened EB-2 (NIW) approved
505 days 2025-05-16
The petitioner proposes to continue research in pharmaceutics, specifically focusing on drug nano-delivery systems and the development of smart, sustainable alternative drug dosage forms. This work utilizes pharmaceutical technology to improve the deliverability, targetability, efficacy, and safety of drugs. The intended impact is to address critical needs in drug formulation and patient care within the United States.
View Case

Postdoctoral Researcher

Biotechnology · China

WeGreened EB-2 (NIW) approved
New York 169 days 2025-04-09
The petitioner proposes to continue research in the development of pharmacokinetics (PK) and pharmacodynamics (PD) studies, specifically focusing on the targeted delivery of anti-tumor and antimicrobial medications. This work involves synthesizing bioactive polymers, spatial metabolomics, and protein engineering to improve therapeutic efficacy. The endeavor aims to advance precision medications that reduce side effects for challenging diseases.
View Case

Postdoctoral Researcher

Chemicals · India

WeGreened EB-2 (NIW) approved
Massachusetts 156 days 2022-10-04
The petitioner proposes to continue research on developing state-of-the-art drug delivery approaches that cross biological interfaces. This work focuses on enabling the facile treatment of a wide range of disorders, including neurological disorders, metastatic cancer, and COVID-19, through protein-based therapies.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from India

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-02-08.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 111 days
RFE Issued
Criteria Met 3 / 3
Evidence Types 6

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in India All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist